May 28, 2025
Platform
Using the latest advanced chemistry techniques, our platform is engineered with three critical components:
Minimizes off-target effects, supports higher therapeutic index
Supports low free payload release in circulation
Supports optimal dosing
Minimizes off-target effects, supports higher therapeutic index
Supports low free payload release in circulation
Supports optimal dosing
This next wave ADC platform from Hangzhou DAC (known as CPT113) is designed to reduce the lower bound of the minimally effective dose with more potent targeting, while raising the upper bound of the maximally tolerated dose with optimized payloads. This leads to the potential for increased dose intensity and improved efficacy.
Targeting
Whitehawk Therapeutics is taking a thoughtful approach to targeting by identifying targets clinically validated by previous pharmaceutical efforts, but where substantial room exists for new entrants. We believe PTK7, MUC16 and SEZ6 may offer similar potential to other well validated targets, like HER2, HER3 and TROP2. Each target has multi-tumor indication potential and utilizes best-in-class targeting approaches with novel mABs uniquely designed for each target.